In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...

The current analysis involved the participants with both obesity and prediabetes, who received their assigned dose of tirzepatide or placebo for a total of 176 weeks, followed by a 17-week off ...

Of the original 1032 randomly assigned, the proportions completing the study ranged from 69.6% with the 5 mg tirzepatide dose ...

Factors like insurance coverage, drug availability, and side effects also influence physicians’ choices, with some patients benefiting from the broader dosing options that tirzepatide offers.

The initial seven day dosing phase of either an oral DehydraTECH-processed tirzepatide capsule or a single injected tirzepatide dose is scheduled to be completed on October 13th. After a multi ...

"Yet many entities continue to mass produce unapproved tirzepatide knockoffs that may expose patients to potentially life-threatening risks, including versions that are manipulated as to dose and ...

Tirzepatide demonstrated sustained average weight loss of 22.9% (15 mg dose) through the three-year treatment period. The study showed an association of tirzepatide treatment with improved ...